Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has issued an appraisal consultation document for the use of ranibizumab for macular oedema due to retinal vein occlusion, and makes the following preliminary recommendation:
. Ranibizumab is not recommended for the treatment of visual impairment caused by macular oedema secondary to central or branch retinal vein occlusion.
The closing date for comments is 15 December 2011
Uncategorized